Last updated on May 2020

Study of Out of Specification for Tisagenlecleucel

Brief description of study

This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product.

Specifically, this study will evaluate the safety of tisagenlecleucel in pediatric/young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (pALL) and adult patients with r/r large B-cell lymphoma (LBCL) including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the product information for tisagenlecleucel in the respective country/region. In addition to safety, key efficacy of tisagenlecleucel that is out of specification (OOS) for commercial release will also be evaluated.

Detailed Study Description

Patients whose final manufactured tisagenlecleucel batches do not meet the approved local commercial release specifications are eligible for inclusion.Each case will be individually assessed for the expected benefit risk profile prior to release to the patient. Following the infusion of OOS tisagenlecleucel, the patient will be followed for 3 months on this study.

Clinical Study Identifier: NCT04094311

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.